Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study
2020
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
25
Citations
NaN
KQI